Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2024 Jun;44(6):1316-1328.
doi: 10.1111/liv.15880. Epub 2024 Feb 26.

Disparities among ethnic groups in mortality and outcomes among adults with MASLD: A multicenter study

Affiliations
Multicenter Study

Disparities among ethnic groups in mortality and outcomes among adults with MASLD: A multicenter study

Majd B Aboona et al. Liver Int. 2024 Jun.

Abstract

Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the leading cause of chronic liver disease and 10%-20% occurs in lean individuals. There is little data in the literature regarding outcomes in an ethnically-diverse patient populations with MASLD. Thus, we aim to investigate the natural history and ethnic disparities of MASLD patients in a diverse population, and stratified by body mass index categories.

Methods: We conducted a retrospective multicenter study on patients with MASLD at the Banner Health System from 2012 to 2022. Main outcomes included mortality and incidence of cirrhosis, cardiovascular disease, diabetes mellitus (DM), liver-related events (LREs), and cancer. We used competing risk and Cox proportional hazard regression analysis for outcome modelling.

Results: A total of 51 452 (cross-sectional cohort) and 37 027 (longitudinal cohort) patients were identified with 9.6% lean. The cohort was 63.33% European ancestry, 27.96% Hispanic ancestry, 3.45% African ancestry, and 2.31% Native American/Alaskan ancestry. Median follow-up was 45.8 months. After adjusting for confounders, compared to European individuals, Hispanic and Native American/Alaskan patients had higher prevalence of cirrhosis and DM, and individuals of Hispanic, African, and Native American/Alaskan ancestry had higher mortality and incidence of LREs and DM. Lean patients had higher mortality and incidence of LREs compared with non-lean patients.

Conclusion: Native American/Alaskan, Hispanic, and African patients had higher mortality and incidence of LREs and DM compared with European patients. Further studies to explore the underlying disparities and intervention to prevent LREs in lean patients, particularly several ethnic groups, may improve clinical outcomes.

Keywords: Hispanic paradox; MASLD; Native Americans; ethnic disparities; liver decompensation.

PubMed Disclaimer

Conflict of interest statement

VLC received research funding from AstraZeneca and KOWA (to University of Michigan). CN has served as a consultant for Boxer Capital. DQH has served as an advisory board member for Eisai and receives funding support from the Singapore Ministry of Health’s National Medical Research Council under its NMRC Research Training Fellowship (MOH-000595–01). MBA, CSF, PR, MM, MNR, MH, MBF, DK, and KW have no conflict of interest.

Figures

FIGURE 1
FIGURE 1
Study flowchart.
FIGURE 2
FIGURE 2
Cumulative incidence of death and diseases among MASLD by BMI category. (A) Cumulative incidence of death by BMI category. (B) Cumulative incidence of cardiovascular disease by BMI category. (C) Cumulative incidence of liver-related events by BMI category. (D) Cumulative incidence of cirrhosis by BMI category. (E) Cumulative incidence of cancer by BMI category. (F) Cumulative incidence of Type II diabetes mellitus by BMI category. BMI, body mass index; MASLD, metabolic dysfunction-associated steatotic liver disease.

Similar articles

Cited by

References

    1. Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335–1347. - PMC - PubMed
    1. Le MH, Yeo YH, Zou B, et al. Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach. Clin Mol Hepatol 2022;28(4):841–850. - PMC - PubMed
    1. Simon TG, Roelstraete B, Khalili H, Hagstrom H, Ludvigsson JF. Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort. Gut 2021;70(7):1375–1382. - PMC - PubMed
    1. Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol 2016;65(3):589–600. - PubMed
    1. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40(6):1387–1395. - PubMed

Publication types

MeSH terms